Navigation Links
Advanced Life Sciences to Host Conference Call to Discuss Announcement Made Yesterday by FDA to Conduct Advisory Panel on CAP Drug Development
Date:1/18/2008

CHICAGO, Jan. 18 /PRNewswire-FirstCall/ -- Advanced Life Sciences Holdings, Inc. (Nasdaq: ADLS), today announced that it will host a conference call and live webcast at 10:30 am (EST) on Tuesday, January 22, 2008. The focus of the call will be to discuss the announcement that was made yesterday by the US Food & Drug Administration (FDA) to host an upcoming meeting of the Anti-Infective Drugs Advisory Committee to discuss product development and clinical trial design for community acquired pneumonia (CAP).

(Logo: http://www.newscom.com/cgi-bin/prnh/20050428/CGTH039LOGO)

Conference Call Details:

The conference call will be webcast simultaneously over the Internet. Please visit the Investor Relations section of the Advanced Life Sciences corporate website http://www.advancedlifesciences.com. Alternatively, callers may participate in the conference call by dialing 888-679-8018 (domestic) or 617-213-4845(international). The passcode for the conference call is 17138842. A replay of the conference call will be available until February 18, 2008. Callers may access the telephone replay by dialing 888-286-8010 (domestic) or 617-801-6888 (international), passcode 98574223. Investors are advised to dial into the call at least ten minutes prior to the call to register. Participants may pre-register for the call at https://www.theconferencingservice.com/prereg/key.process?key=PQVH73VRK. Pre-registrants will be issued a pin number to use when dialing into the live call which will provide quick access to the conference by bypassing the operator upon connection.

About Advanced Life Sciences

Advanced Life Sciences is a biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs in the therapeutic areas of infection, cancer and inflammation. The Company's lead candidate, cethromycin, is a novel once-a-day oral antibiotic in late-stage development for the treatment of respiratory tract infections including CAP. For more information, please visit us on the web at http://www.advancedlifesciences.com.

Forward-Looking Statements

Any statements contained in this press release that relate to future plans, events or performance are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements represent our management's judgment regarding future events. The Company does not undertake any obligations to update any forward-looking statements whether as a result of new information, future events or otherwise. Our actual results could differ materially from those discussed herein due to several factors including the success and timing of a commercial partnership and our ability to obtain and maintain regulatory approval and labeling of our product candidates; our plans to develop and commercialize our product candidates; the loss of key scientific or management personnel; the size and growth of potential markets for our product candidates and our ability to serve those markets; regulatory developments in the U.S. and foreign countries; the rate and degree of market acceptance of any future products; the accuracy of our estimates regarding expenses, future revenues and capital requirements; our ability to obtain financing on terms acceptable to us; our ability to obtain and maintain intellectual property protection for our product candidates; the successful development of our sales and marketing capabilities; the success of competing drugs that become available; and the performance of third party collaborators and manufacturers. These and additional risks and uncertainties are detailed in the Company's filings with the Securities and Exchange Commission.


'/>"/>
SOURCE Advanced Life Sciences Holdings, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Derma Sciences Expands Direct Sales Force for Advanced Wound Care, Looks to Double Again in 2008
2. Cardica and Intuitive Surgical to Host Educational Symposium on Advanced Techniques and Technologies in Robotic Coronary Revascularization and Mitral Valve Repair
3. Advanced Energy Consortium will develop micro and nanosensors to boost energy production
4. Transgenes Therapeutic Vaccine TG4010 Shows Promising Preliminary Phase IIb Data in Advanced Non-Small Cell Lung Cancer
5. Advanced Life Sciences to Present at Biodefense Session of 26th Annual JPMorgan Healthcare Conference
6. Avastin Approved in Europe for First-Line Treatment of Patients With Advanced Kidney Cancer
7. Medco Chooses AllPoints at Anson in Whitestown, Indiana as Site for the Worlds Largest, Most-Advanced Automated Pharmacy
8. Advanced Life Sciences Enters Into Definitive Securities Purchase Agreements for $20 Million with New and Existing Institutional Investors
9. Young Physicians Demanding Advanced Laparoscopic Energy Instruments
10. Model for the assembly of advanced, single-molecule-based electronic components developed at Pitt
11. EDDA Technology Introduces Universal Enterprise Solution - Enabling 2D/3D/4D Advanced Clinical Applications on Existing PACS Workstations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... has an active R&D program for the development ... the Group has a unique research and development center in ... developing Bio Control products. Stockton has ... and regulatory guidelines, and is active in more than 35 ... Stockton,s flagship product Timorex Gold ® ...
(Date:2/6/2016)... ... February 06, 2016 , ... Contact:, Abby Mitchell, Communications Manager, ... Education Sponsors Teacher Training Program , Bite of Science Dinner Event to Strengthen ... Excellence in Education (CEE) will sponsor a Bite of Science professional enrichment session, ...
(Date:2/5/2016)... 2016 Amarantus BioScience Holdings, Inc. ... on developing products for Regenerative Medicine, Neurology and Orphan ... Designation (RPDD) from the US Food and Drug Administration ... was previously granted orphan drug designation (ODD) by the ... BioScience Holdings, Inc. (OTCQB: AMBS), a ...
(Date:2/4/2016)... RICHMOND, Calif. , Feb. 4, 2016  Sangamo ... therapeutic genome editing, announced today that Edward Lanphier ... an update on the progress of Sangamo,s ZFP Therapeutic ... company,s business strategy at 2:40 pm ET on Thursday, ... Annual Global Healthcare Conference. The conference is being ...
Breaking Biology Technology:
(Date:1/22/2016)... 22, 2016 ... of the  "Global Behavioral Biometric Market ... --> http://www.researchandmarkets.com/research/4lmf2s/global_behavioral ) has announced ... Biometric Market 2016-2020"  report to their ... Markets ( http://www.researchandmarkets.com/research/4lmf2s/global_behavioral ) has announced the ...
(Date:1/20/2016)... , Jan. 20, 2016   MedNet Solutions , ... entire spectrum of clinical research, is pleased to announce ... significant achievements are the result of the company,s laser ... iMedNet eClinical , it,s comprehensive, easy-to-use and highly ... --> Key MedNet growth achievements in 2015 ...
(Date:1/13/2016)... New York , January 13, 2016 ... Market Research has published a new market report titled ... Growth, Trends, and Forecast, 2015 - 2023. According to the ... in 2014 and is anticipated to reach US$1,625.8 mn ... 2015 to 2023. In terms of volume, the biometric ...
Breaking Biology News(10 mins):